Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study

 ・Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan.
・The study data will be used to support a New Drug Application (NDA) for TLX591-Px in Japan. MELBOURNE, Australia and TOKYO, July 17, 2026 /PRNewswire/ -- Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX, "Telix") today announced completion of patient enrollment in the pivotal Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of 68Ga-PSMA-11[1]) for prostate cancer imaging in Japanese patients. Illuccix Japan[2] is a Phase 3 prospect…READ FULL ARTICLE